Cargando…
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313647/ https://www.ncbi.nlm.nih.gov/pubmed/28083945 http://dx.doi.org/10.1002/cam4.964 |
_version_ | 1782508379984363520 |
---|---|
author | Koleck, Theresa A. Bender, Catherine M. Sereika, Susan M. Ryan, Christopher M. Ghotkar, Puja Brufsky, Adam M. Jankowitz, Rachel C. McAuliffe, Priscilla F. Clark, Beth Z. Conley, Yvette P. |
author_facet | Koleck, Theresa A. Bender, Catherine M. Sereika, Susan M. Ryan, Christopher M. Ghotkar, Puja Brufsky, Adam M. Jankowitz, Rachel C. McAuliffe, Priscilla F. Clark, Beth Z. Conley, Yvette P. |
author_sort | Koleck, Theresa A. |
collection | PubMed |
description | Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant therapy cognitive performance in postmenopausal women newly diagnosed with early‐stage breast cancer. Participants (N = 329) completed a comprehensive battery of neuropsychological tests to evaluate cognitive performance after primary surgery but prior to initiation of adjuvant anastrozole±chemotherapy. PTF data were abstracted from medical records. Robust multiple linear regression models were fit to estimate associations between individual PTFs and the cognitive function composite domain scores. All models controlled for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. Diagnosis of a HER2‐positive tumor contributed to poorer verbal (b = −0.287, P = 0.018), visual (b = −0.270, P = 0.001), and visual working (b = −0.490, P < 0.001) memory performance compared to diagnosis of a HER2‐negative tumor. Similarly, as HER2 immunohistochemistry classification score increased, verbal (b = −0.072, P = 0.093), visual (b = −0.081, P = 0.003), and visual working (b = −0.170, P < 0.001) memory performance score decreased. Associations with performance were also noted between location, focality/centricity, hormone receptor expression, cellular proliferation (i.e., Ki67), and Oncotype DX (®) Breast Cancer Assay Recurrence Score(®).) Our results suggest that certain PTFs related to more aggressive tumor phenotypes or inferior breast cancer prognosis may be implicated in poorer preadjuvant therapy cognitive performance. Follow‐up studies that include a cognitive assessment before primary surgery should be conducted to further delineate the role of intertumor heterogeneity on cognitive performance. |
format | Online Article Text |
id | pubmed-5313647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53136472017-02-24 Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer Koleck, Theresa A. Bender, Catherine M. Sereika, Susan M. Ryan, Christopher M. Ghotkar, Puja Brufsky, Adam M. Jankowitz, Rachel C. McAuliffe, Priscilla F. Clark, Beth Z. Conley, Yvette P. Cancer Med Clinical Cancer Research Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant therapy cognitive performance in postmenopausal women newly diagnosed with early‐stage breast cancer. Participants (N = 329) completed a comprehensive battery of neuropsychological tests to evaluate cognitive performance after primary surgery but prior to initiation of adjuvant anastrozole±chemotherapy. PTF data were abstracted from medical records. Robust multiple linear regression models were fit to estimate associations between individual PTFs and the cognitive function composite domain scores. All models controlled for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. Diagnosis of a HER2‐positive tumor contributed to poorer verbal (b = −0.287, P = 0.018), visual (b = −0.270, P = 0.001), and visual working (b = −0.490, P < 0.001) memory performance compared to diagnosis of a HER2‐negative tumor. Similarly, as HER2 immunohistochemistry classification score increased, verbal (b = −0.072, P = 0.093), visual (b = −0.081, P = 0.003), and visual working (b = −0.170, P < 0.001) memory performance score decreased. Associations with performance were also noted between location, focality/centricity, hormone receptor expression, cellular proliferation (i.e., Ki67), and Oncotype DX (®) Breast Cancer Assay Recurrence Score(®).) Our results suggest that certain PTFs related to more aggressive tumor phenotypes or inferior breast cancer prognosis may be implicated in poorer preadjuvant therapy cognitive performance. Follow‐up studies that include a cognitive assessment before primary surgery should be conducted to further delineate the role of intertumor heterogeneity on cognitive performance. John Wiley and Sons Inc. 2017-01-13 /pmc/articles/PMC5313647/ /pubmed/28083945 http://dx.doi.org/10.1002/cam4.964 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Koleck, Theresa A. Bender, Catherine M. Sereika, Susan M. Ryan, Christopher M. Ghotkar, Puja Brufsky, Adam M. Jankowitz, Rachel C. McAuliffe, Priscilla F. Clark, Beth Z. Conley, Yvette P. Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title_full | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title_fullStr | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title_full_unstemmed | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title_short | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
title_sort | associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313647/ https://www.ncbi.nlm.nih.gov/pubmed/28083945 http://dx.doi.org/10.1002/cam4.964 |
work_keys_str_mv | AT kolecktheresaa associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT bendercatherinem associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT sereikasusanm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT ryanchristopherm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT ghotkarpuja associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT brufskyadamm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT jankowitzrachelc associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT mcauliffepriscillaf associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT clarkbethz associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer AT conleyyvettep associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer |